Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)

A legfontosabb adatok

Ki végzi
University of Edinburgh
Hol
Egyesült Királyság1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
30 fő, tervezett
Kezdés
2026. okt.
Várható befejezés
2029. jún.
A vizsgálat típusa
Megfigyeléses, 3 csoport
A vizsgált kezelések
  • Zirconium Zr 89 labelled rituximab
A regiszteradat frissítve
2026. június 16.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with newly diagnosed, active giant cell arteritis of the large blood vessels. It also takes two comparison groups: people with an immune disorder driven by B cells, and people with a bulging main artery (aortic aneurysm) caused by fatty build-up.

Életkor
GCA group and aneurysm group: 50 years or older. B-cell immune disorder group: 18 years or older.
Nem
All sexes can join.
A betegség stádiuma
GCA group: meets the 2022 American College of Rheumatology/EULAR criteria for giant cell arteritis, with scans showing active large-vessel GCA in the previous 4 weeks. B-cell group: active disease according to the referring team. Aneurysm group: scans showing an atherosclerotic aortic aneurysm.
Korábbi kezelés
GCA group: will be treated with steroids (corticosteroids) alone by the care team. People who took corticosteroids for more than 4 weeks right before the study start cannot join.

A részvétel fő kizáró okai

  • A previous diagnosis of GCA
  • Pregnancy or breastfeeding
  • Severe kidney problems (eGFR <15ml/min/1.73m2)
  • Another major illness that the study doctor thinks rules out taking part
  • Unable to give consent, or unable or unwilling to follow radiation safety advice

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • For GCA group:; Adults ≥ 50 years at the time of enrolment; Meets 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis; Imaging evidence of active LV-GCA in the previous 4 weeks; Will be managed with corticosteroid monotherapy by the standard care team; For BCMID group:
  • Adults ≥ 18 years at the time of enrolment
  • Meets criteria for a diagnosis of a B-cell mediated immune disorder
  • Considered to have active disease by referring team
  • Will be managed as per standard of care by referring team; For AA group:
  • Adults ≥ 50 years at the time of enrolment
  • Imaging evidence of atherosclerotic aortic aneurysm

Ki nem vehet részt

  • Participants receiving corticosteroids for >4 weeks immediately prior to baseline
  • Previous diagnosis of GCA
  • Inability or unwillingness to comply with the radiation protection advice
  • History of any major morbidity which the clinical investigator considers contraindicated to study entry
  • Advanced renal dysfunction (eGFR <15ml/min/1.73m2)
  • Pregnancy or breastfeeding
  • Patients without mental capacity or willingness to provide informed consent

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

B cells are a component of the immune system which appear be important in causing all forms of cardiovascular disease. Until now, it has not been possible to directly study these cells in living patients (essential to assess their potential as the target of new treatments). For the first time in any cardiovascular disease, this study will apply cutting edge scanning technology to visualise B cells in the blood vessels of giant cell arteritis (GCA) patients. GCA is a common and potentially deadly disorder of the blood vessels which is caused by abnormalities of the immune system. Current treatments are mainly limited to steroids. Unfortunately, these drugs bring tremendous side effects and so there is an urgent requirement to discover alternatives.

A teljes eredeti leírásKevesebb

Laboratory investigations tell us that B cells are highly present in GCA and so if the proposed scanning technology fails to identify these cells in the blood vessels of participants, then the technology is unlikely to be useful for other cardiovascular diseases. If, however, the study does successfully visualise B cells, this knowledge could pave the way for clinical trials of B cell targeted treatments (already established in other conditions) as steroid alternatives in GCA.

This study aims to map the distribution of the radiotracer zirconium-89 labelled rituximab within the blood vessels of patients with newly diagnosed GCA and compare this with two separate control groups without the condition. This will allow us to determine the role of B cells within this condition, and whether patients would benefit from B cell-depleting treatments such as rituximab.

A vizsgálat 3 csoportja

  • LV-GCA group

    Patients with a diagnosis of active, large vessel GCA

    Kezelés: Zirconium Zr 89 labelled rituximab

  • AA control group

    Patients with a diagnosis of atherosclerotic aortic aneurysm

    Kezelés: Zirconium Zr 89 labelled rituximab

  • BCMID control group

    Patients with a diagnosis of a B-cell mediated inflammatory disorder

    Kezelés: Zirconium Zr 89 labelled rituximab

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. június 16.